FDA Rejects Novo’s Diabetes Drugs, Wants Heart Study

Drug Industry Daily
A A
The FDA has denied approval of Novo Nordisk’s Type 1 and Type 2 diabetes drugs Tresiba and Ryzodeg, requesting a dedicated cardiovascular outcomes trial.

To View This Article:

Login

Subscribe To Drug Industry Daily